English Polski

Wyszuk. zaawans.

Tom 15, Supl. A (2020)
Artykuł przeglądowy
Opublikowany online: 2020-05-27

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 653
Wyświetlenia/pobrania artykułu 2345
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Lipemia poposiłkowa — problem kliniczny i potencjalne miejsce w algorytmach diagnostycznych Stanowisko polskich ekspertów

Anna Skoczyńska1, Marta Wawrzynowicz-Syczewska2, Marta Barlik-Rysa3, Andrzej Danik4, Jacek Różański5, Krzysztof J. Filipiak6, Barbara Cybulska7
DOI: 10.5603/FC.2020.0001

Streszczenie

W poniższym opracowaniu przedstawiono stanowiska ekspertów z różnych towarzystw, głównie europejskich, dotyczące roli hipertriglicerydemii (HTG) poposiłkowej w przewidywaniu ryzyka sercowo-naczyniowego (CV). Uwzględniono nowe badania i różne kategorie pacjentów. Oparto się głównie na wytycznych European Society of Cardiology i European Atherosclerosis Society z 2019 roku, dotyczących postępowania w dyslipidemii, oraz panelu Postprandial hypertriglyceridaemia revisited in era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, main text. Przedstawiono także stanowisko polskich ekspertów stosujących doustny test tolerancji tłuszczów w praktyce klinicznej. Problemem pozostaje ocena roli HTG w szacowaniu ryzyka CV oraz ustalenie, czy spożycie standardowego wysokotłuszczowego preparatu, a następnie pobranie krwi we wskazanym przedziale czasowym, czyli doustny test tolerancji tłuszczów, może poprawić ocenę ryzyka CV. Znaczenie HTG poposiłkowej w ocenie ryzyka aterogennego jest coraz lepiej udokumentowane, jakkolwiek istnieje potrzeba dalszych badań.

Słowa kluczowe: hipertriglicerydemiaryzyko sercowo-naczyniowedoustny test tolerancji tłuszczów (OFTT)

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
    CrossRefPubMed
  2. Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, main text. Curr Vasc Pharmacol. 2019; 17(5): 498–514.
    CrossRefPubMed
  3. Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841): 581–590.
    CrossRefPubMed
  4. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018; 319(15): 1566–1579.
    CrossRefPubMed
  5. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014; 64(5): 485–494.
    CrossRefPubMed
  6. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B): 2889–2934.
    CrossRefPubMed
  7. National Institute for Health and Care Excellence (NICE). Clinical guideline CG181: lipid modification — cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Clinical Guideline Centre 2014. https://www.nice.org.uk/guidance/cg181 (3.12.2019).
  8. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016; 32(11): 1263–1282.
    CrossRefPubMed
  9. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316(19): 1997–2007.
    CrossRefPubMed
  10. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members:, Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers:, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
    CrossRefPubMed
  11. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–1681.
    CrossRefPubMed
  12. Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011; 57(16): 1666–1675.
    CrossRefPubMed
  13. McCormack T, Dent R, Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract. 2016; 70(11): 886–897.
    CrossRefPubMed
  14. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18): 1713–1722.
    CrossRefPubMed
  15. Ray KK, Colhoun HM, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators, ODYSSEY OUTCOMES Committees and Investigators, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379(22): 2097–2107.
    CrossRefPubMed
  16. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
    CrossRefPubMed
  17. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18): 1713–1722.
    CrossRefPubMed
  18. Ridker PM, Revkin J, Amarenco P, et al. SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017; 376(16): 1527–1539.
    CrossRefPubMed
  19. Bowman L, Hopewell JC, Chen F, et al. HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017; 377(13): 1217–1227.
    CrossRefPubMed
  20. Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12): 1119–1131.
    CrossRefPubMed
  21. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011; 9(3): 258–270.
    CrossRefPubMed
  22. Chapman MJ, Ginsberg HN, Amarenco P, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11): 1345–1361.
    CrossRefPubMed
  23. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384(9943): 626–635.
    CrossRefPubMed
  24. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118(4): 547–563.
    CrossRefPubMed
  25. Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016; 9(2): 100–108.
    CrossRefPubMed
  26. Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012; 125(16): 1979–1987.
    CrossRefPubMed
  27. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018; 138(8): 770–781.
    CrossRefPubMed
  28. Faergeman O, Holme I, Fayyad R, et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009; 104(4): 459–463.
    CrossRefPubMed
  29. Lawler PR, Akinkuolie AO, Chu AY, et al. Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol. J Am Heart Assoc. 2017; 6(7).
    CrossRefPubMed
  30. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3): 299–308.
    CrossRefPubMed
  31. Varbo A, Benn M, Nordestgaard BG, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61(4): 427–436.
    CrossRefPubMed
  32. Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013; 128(12): 1298–1309.
    CrossRefPubMed
  33. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016; 48(6): 634–639.
    CrossRefPubMed
  34. Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015; 116(4): 665–673.
    CrossRefPubMed
  35. Jørgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013; 34(24): 1826–1833.
    CrossRefPubMed
  36. Jepsen AMK, Langsted A, Varbo A, et al. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clin Chem. 2016; 62(4): 593–604.
    CrossRefPubMed
  37. Varbo A, Freiberg JJ, Nordestgaard BG. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study. Clin Chem. 2018; 64(1): 219–230.
    CrossRefPubMed
  38. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. Eur Heart J. 2016; 37(25): 1944–1958.
    CrossRefPubMed
  39. Di Angelantonio E, Gao P, Pennells L, et al. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307(23): 2499–2506.
    CrossRefPubMed
  40. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016; 316(12): 1289–1297.
    CrossRefPubMed
  41. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726): 1634–1639.
    CrossRefPubMed
  42. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015; 36(1): 131–147.
    CrossRefPubMed
  43. Dron JS, Hegele RA. Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr Opin Lipidol. 2017; 28(2): 161–169.
    CrossRefPubMed
  44. Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019; 321(4): 364–373.
    CrossRefPubMed
  45. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE. ed. ietz textbook of clinical chemistry and molecular diagnostics. Elsevier Saunders, Philadelphia 2006: 903–982.
  46. Simundic AM, Cornes M, Grankvist K, et al. Standardization of collection requirements for fasting samples: for the Working Group on Preanalytical Phase (WG-PA) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Clin Chim Acta. 2014; 432: 33–37.
    CrossRefPubMed
  47. Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. The prevalence of metabolic syndrome in various populations. Am J Med Sci. 2007; 333(6): 362–371.
    CrossRefPubMed
  48. Nordestgaard B. A test in context: lipid profile, fasting versus nonfasting. Journal of the American College of Cardiology. 2017; 70(13): 1637–1646.
    CrossRef
  49. Pikto Pietkiewicz I, Boden WE, Probstfield JL, et al. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24): 2255–2267.
    CrossRefPubMed
  50. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008; 300(18): 2142–2152.
    CrossRefPubMed
  51. Catapano AL, Graham I, De Backer G, et al. Additional Contributor, Authors/Task Force Members:, ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
    CrossRefPubMed
  52. Leung AA, Nerenberg K, Daskalopoulou SS, et al. CHEP Guidelines Task Force. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2016; 32(5): 569–588.
    CrossRefPubMed
  53. Scartezini M, Ferreira CE, Izar MC, et al. Positioning about the flexibility of fasting for lipid profiling. Arq Bras Cardiol. 2017; 108(3): 195–197.
    CrossRefPubMed
  54. Miller M, Stone NJ, Ballantyne C, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123(20): 2292–2333.
    CrossRefPubMed
  55. Ooi EMM, Watts GF, Ng TWK, et al. Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients. 2015; 7(6): 4416–4425.
    CrossRefPubMed
  56. Borén J, Matikainen N, Adiels M, et al. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014; 431: 131–142.
    CrossRefPubMed
  57. Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Curr Vasc Pharmacol. 2011; 9(3): 292–301.
    CrossRefPubMed
  58. Boekholdt SM, Hovingh GK, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307(12): 1302–1309.
    CrossRefPubMed
  59. Shaikh M, Wootton R, Nordestgaard BG, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991; 11(3): 569–577.
    CrossRefPubMed
  60. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb. 1992; 12(1): 6–18.
    CrossRefPubMed
  61. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995; 15(4): 534–542.
    CrossRefPubMed
  62. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016; 12: 171–183.
    CrossRefPubMed
  63. Dallinga-Thie GM, Kroon J, Borén J, et al. Triglyceride-rich lipoproteins and remnants: targets fortherapy? Curr Cardiol Rep. 2016; 18(7): 67.
    CrossRefPubMed
  64. Nordestgaard BG. Test in context: lipid profile, fasting versus nonfasting. Am Coll Cardiol. 2017; 70(13): 1637–1646.
    CrossRefPubMed
  65. Rosenson RS, Helenowski IB, Tangney CC. Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. Cardiovasc Drugs Ther. 2010; 24(5-6): 439–447.
    CrossRefPubMed
  66. Pavlidis AN, Kolovou GD, Anagnostopoulou KK, et al. Postprandial metabolic heterogeneity in men with primary dyslipidaemia. Arch Med Sci. 2010; 6(6): 879–886.
    CrossRefPubMed
  67. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, et al. Metabolic syndrome and gender differences in postprandial lipaemia. Eur J Cardiovasc Prev Rehabil. 2006; 13(4): 661–664.
    CrossRefPubMed
  68. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298(3): 309–316.
    CrossRefPubMed
  69. Lindman AS, Veierød MB, Tverdal A, et al. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur J Epidemiol. 2010; 25(11): 789–798.
    CrossRefPubMed
  70. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500): 1849–1861.
    CrossRefPubMed
  71. Reyes-Soffer G, Ngai CI, Lovato L, et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care. 2013; 36(2): 422–428.
    CrossRefPubMed
  72. Elam MB, Ginsberg HN, Lovato LC, et al. ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017; 2(4): 370–380.
    CrossRefPubMed
  73. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016; 39(5): 701–708.
    CrossRefPubMed
  74. Scott R, O'Brien R, Fulcher G, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32(3): 493–498.
    CrossRefPubMed
  75. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000; 102(1): 21–27.
    CrossRefPubMed
  76. Rubins H, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999; 341(6): 410–418.
    CrossRefPubMed
  77. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988; 260(5): 641–651.
    PubMed
  78. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000; 102(1): 21–27.
    CrossRefPubMed
  79. Miller M, Stone NJ, Ballantyne C, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123(20): 2292–2333.
    CrossRefPubMed
  80. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol. 2011; 9(3): 271–280.
    CrossRefPubMed
  81. Perez-Martinez P, Alcala-Diaz JF, Kabagambe EK, et al. Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. J Clin Lipidol. 2016; 10(5): 1163–1171.
    CrossRefPubMed
  82. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb. 1992; 12(1): 6–18.
    CrossRefPubMed
  83. Niederwanger A, Ciardi C, Tatarczyk T, et al. Postprandial lipemia induces pancreatic α cell dysfunction characteristic of type 2 diabetes: studies in healthy subjects, mouse pancreatic islets, and cultured pancreatic α cells. Am J Clin Nutr. 2014; 100(5): 1222–1231.
    CrossRefPubMed
  84. Mattes RD. Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans. Am J Physiol Gastrointest Liver Physiol. 2009; 296(2): G365–G371.
    CrossRefPubMed
  85. Schneeman BO, Kotite L, Todd KM, et al. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993; 90(5): 2069–2073.
    CrossRefPubMed
  86. Cohn JS, Johnson EJ, Millar JS, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 1993; 34(12): 2033–2040.
    PubMed
  87. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49(4): 755–765.
    CrossRefPubMed
  88. Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr. 2005; 81(1): 35–42.
    CrossRefPubMed
  89. Matikainen N, Adiels M, Söderlund S, et al. Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins. Obesity (Silver Spring). 2014; 22(8): 1854–1859.
    CrossRefPubMed
  90. Berglund L, Brunzell JD, Goldberg AC, et al. Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(9): 2969–2989.
    CrossRefPubMed
  91. Nordestgaard B, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cutpoints — a Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2020; 62(7): 930–946.
    CrossRef
  92. https://www.nice.org.uk/guidance/cg181. National Institute for Health and Care Excellence (NICE). Clinical guideline CG181: Lipid modification - cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Clinical Guideline Centre 2014. (3.12.2019).
  93. Downs JR, O'Malley PG. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2015; 163(4): 291–297.
    CrossRefPubMed
  94. Jacobson TA, Maki KC, Orringer CE, et al. NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol. 2015; 9(6 Suppl): S1–122.e1.
    CrossRefPubMed
  95. Jellinger PS, Handelsman Y, Rosenblit P, et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017; 23(Suppl2): 1–87.
    CrossRef
  96. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/APhA/ASP C/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of cardiology/American Heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018; pii: S0735-1097(18)39033-8.
  97. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018; 138(8): 770–781.
    CrossRefPubMed
  98. Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380(1): 11–22.
    CrossRefPubMed
  99. Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010; 126(3): 314–345.
    CrossRefPubMed
  100. Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine. 2010; 362(17): 1563–1574.
    CrossRef
  101. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005; 366(9500): 1849–1861.
    CrossRef
  102. Catapano AL, Farnier M, Foody JM, et al. Combination therapy in dyslipidemia: where are we now? Atherosclerosis. 2014; 237(1): 319–335.
    CrossRefPubMed
  103. Brahm AJ, Hegele RA. Chylomicronaemia — current diagnosis and future therapies. Nat Rev Endocrinol. 2015; 11(6): 352–362.
    CrossRefPubMed
  104. Bauer RC, Khetarpal SA, Hand NJ, et al. Therapeutic targets of triglyceride metabolism as informed by human genetics. Trends Mol Med. 2016; 22(4): 328–340.
    CrossRefPubMed
  105. Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013; 20(4): 361–369.
    CrossRefPubMed
  106. Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res. 2013; 112(11): 1405–1408.
    CrossRefPubMed
  107. Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profiles: Executive Summary of a 2019 Expert Panel Statement. Curr Vasc Pharmacol. 2019; 17(5): 538–540.
    CrossRefPubMed
  108. Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, narrative review.arrative Review. Curr Vasc Pharmacol. 2019; 17(5): 515–537.
    CrossRefPubMed
  109. Alcala-Diaz JF, Delgado-Lista J, Perez-Martinez P, et al. Hypertriglyceridemia influences the degree of postprandial lipemic response in patients with metabolic syndrome and coronary artery disease: from the CORDIOPREV study. PLoS One. 2014; 9(5): e96297.
    CrossRefPubMed
  110. Wojczynski MK, Parnell LD, Pollin TI, et al. Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). Metabolism. 2015; 64(10): 1359–1371.
    CrossRefPubMed
  111. Kolovou GD, Salpea KD, Anagnostopoulou KK, et al. Alcohol use, vascular disease, and lipid-lowering drugs. J Pharmacol Exp Ther. 2006; 318(1): 1–7.
    CrossRefPubMed
  112. Ooi TC, Nordestgaard BG. Methods to study postprandial lipemia. Curr Vasc Pharmacol. 2011; 9(3): 302–308.
    CrossRefPubMed
  113. Tsetsonis NV, Hardman AE, Mastana SS. Acute effects of exercise on postprandial lipemia: a comparative study in trained and untrained middle-aged women. Am J Clin Nutr. 1997; 65(2): 525–533.
    CrossRefPubMed
  114. White KT, Moorthy MV, Akinkuolie AO, et al. Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state. Clin Chem. 2015; 61(9): 1156–1163.
    CrossRefPubMed
  115. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008; 118(20): 2047–2056.
    CrossRefPubMed
  116. Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, et al. CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat diet on cardiovascular disease in coronary patients. Am Heart J. 2016; 177: 42–50.
    CrossRefPubMed
  117. Vors C, Pineau G, Gabert L, et al. Modulating absorption and postprandial handling of dietary fatty acids by structuring fat in the meal: a randomized crossover clinical trial. Am J Clin Nutr. 2013; 97(1): 23–36.
    CrossRefPubMed
  118. Slivkoff-Clark KM, James AP, Mamo JCl. The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men. Nutr Metab (Lond). 2012; 9: 9.
    CrossRefPubMed
  119. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PLoS One. 2016; 11(7): e0158765.
    CrossRefPubMed
  120. Mikolasevic I, Žutelija M, Mavrinac V, et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017; 10: 35–45.
    CrossRefPubMed
  121. Younossi ZM. Non-alcoholic fatty liver disease — a global public health perspective. J Hepatol. 2019; 70(3): 531–544.
    CrossRefPubMed
  122. Armstrong MJ, Marchesini G. Referral pathways for NAFLD fibrosis in primary care — no longer a 'needle in a haystack'. J Hepatol. 2019; 71(2): 246–248.
    CrossRefPubMed
  123. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017; 390(10113): 2627–2642.
    CrossRefPubMed
  124. Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol. 2019; 71(4): 802–810.
    CrossRefPubMed
  125. Gambino R, Bugianesi E, Rosso C, et al. Different serum free fatty acid profiles in NAFLD subjects and healthy controls after oral fat load. Int J Mol Sci. 2016; 17(4): 479.
    CrossRefPubMed
  126. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003; 37(4): 909–916.
    CrossRefPubMed
  127. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004; 126(2): 586–597.
    CrossRefPubMed
  128. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008; 49(5): 831–844.
    CrossRefPubMed
  129. Serfaty L. Metabolic manifestations of hepatitis C virus. Clinics in Liver Disease. 2017; 21(3): 475–486.
    CrossRef
  130. Kawagishi N, Suda G, Nakamura A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One. 2018; 13(12): e0209615.
    CrossRefPubMed
  131. González-Aldaco K, Torres-Reyes LA, Ojeda-Granados C, et al. Immunometabolic effect of cholesterol in hepatitis c infection: implications in clinical management and antiviral therapy. Ann Hepatol. 2018; 17(6): 908–919.
    CrossRefPubMed
  132. Beig J, Orr D, Harrison B, et al. Hepatitis C virus eradication with new interferon-free treatment improves metabolic profile in hepatitis C virus-related liver transplant recipients. Liver Transpl. 2018; 24(8): 1031–1039.
    CrossRefPubMed
  133. Ichikawa T, Miyaaki H, Miuma S, et al. Carotid intima-media thickness and small dense low-density lipoprotein cholesterol increase after one year of treatment with direct-acting antivirals in patients with hepatitis C virus infection. Intern Med. 2019; 58(9): 1209–1215.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Folia Cardiologica

O Via Medica Reklama
Księgarnia (Ikamed) TVMed
Aktualności
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice